Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia

Int J Antimicrob Agents. 2001 May;17(5):415-8. doi: 10.1016/s0924-8579(01)00298-9.

Abstract

The incidence of drug resistance in Mycobacterium tuberculosis (MTB) isolated from our hospital between April 1996 and March 1998 was compared with an earlier study (1993-1995). Thirty (29.7%) of 101 MTB isolates were resistant to one or more anti-TB drugs and 21 (20%) of 101 were multi-drug resistant M. tuberculosis (MDR-TB). Resistance was most common to isoniazid (28.7%), followed by streptomycin (22.8%) and rifampicin (20.8%). Resistance to pyrazinamide and ethambutol was 7.9 and 6.9%, respectively. There was a three-fold increase in resistance compared with the earlier study.

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use*
  • Drug Resistance, Microbial
  • Ethambutol / pharmacology
  • Ethambutol / therapeutic use
  • Female
  • Humans
  • Isoniazid / pharmacology
  • Isoniazid / therapeutic use
  • Male
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis / drug effects*
  • Mycobacterium tuberculosis / isolation & purification
  • Prevalence
  • Pyrazinamide / pharmacology
  • Pyrazinamide / therapeutic use
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Saudi Arabia / epidemiology
  • Streptomycin / pharmacology
  • Streptomycin / therapeutic use
  • Tuberculosis / drug therapy*
  • Tuberculosis / epidemiology
  • Tuberculosis / microbiology
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / epidemiology
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Antitubercular Agents
  • Pyrazinamide
  • Ethambutol
  • Isoniazid
  • Rifampin
  • Streptomycin